Sangamo Therapeutics Inc (SGMO)

4.20
NASDAQ : Health Care
Prev Close 4.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.65 / 7.60
Avg Volume 709.20K
Exchange NASDAQ
Shares Outstanding 70.88M
Market Cap 283.50M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo Therapeutics Announces Chief Financial Officer Succession

Sangamo Therapeutics Announces Chief Financial Officer Succession

Kathy Yi Appointed to Succeed H. Ward Wolff as CFO Upon His Retirement in March

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

Biotech Premarket Movers: BioCryst, Sangamo, Cempra

BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Biotech Premarket Movers: IPXL, SGMO, ARLZ

Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.

Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering

Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering

- New architectures enable targeting of any chosen location in the genome with very high precision

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies

Clear strategy with new management, organizational structure and clinical capabilities will drive Sangamo's industry-leading scientific platform into human studies

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

SB-525 is one of four programs in the Company's newly focused clinical portfolio of in vivo genomic therapies for rare diseases

Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting

Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting

On Track to File Investigational New Drug Application for Hemophilia A Program by End of 2016

Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities

Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities

Dr. Edward Conner Appointed as Senior Vice President and Chief Medical Officer and Curt Herberts Promoted to Newly Created Role of Senior Vice President and Chief Business Officer

Sangamo's Genome Editing Program For Hemoglobinopathies To Transfer To Biogen's Spin-Off Bioverativ

Sangamo's Genome Editing Program For Hemoglobinopathies To Transfer To Biogen's Spin-Off Bioverativ

ZFN-Mediated Genome Editing Programs in Sickle Cell Disease and Beta-Thalassemia Will Move from Biogen to Bioverativ in Line with the Spin-Off Company's Focus on Rare Blood Disorders

Short Interest Expands By 11.8% For SGMO

Short Interest Expands By 11.8% For SGMO

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 918,730 share increase in total short interest for Sangamo BioSciences Inc , to 8,679,778, an increase of 11.84% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Shares of Omeros fell almost 10% after analysts' downgraded the biotech.

Short Interest Falls 12.2% For SGMO

Short Interest Falls 12.2% For SGMO

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,057,847 share decrease in total short interest for Sangamo BioSciences Inc , to 7,636,100, a decrease of 12.17% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Scientists Present Preclinical Data Demonstrating High Levels of Factor VIII Protein Expression from Proprietary Therapeutic AAV cDNA Construct at World Federation of Hemophilia 2016 World Congress